Short- versus long-term, gender and species differences in the intestinotrophic effects of long-acting glucagon-like peptide 2 analog
Jazyk angličtina Země Česko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
35344672
PubMed Central
PMC9150555
DOI
10.33549/physiolres.934839
PII: 934839
Knihovny.cz E-zdroje
- MeSH
- druhová specificita MeSH
- glukagonu podobný peptid 2 * MeSH
- krysa rodu Rattus MeSH
- lidé MeSH
- peptidy farmakologie MeSH
- potkani Wistar MeSH
- psi MeSH
- syndrom krátkého střeva * farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- lidé MeSH
- mužské pohlaví MeSH
- psi MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- glukagonu podobný peptid 2 * MeSH
- peptidy MeSH
Glucagon-like-peptide 2 (GLP-2) is an endogenous enteroendocrine physiological trophic peptide. Glepaglutide is a novel long-acting GLP-2 analog under development for the treatment of patients with Short Bowel Syndrome (SBS). The objective of this work was to compare the small intestinal trophic effects in both genders following short (1 week) versus long-term (26-39 weeks) GLP-2 treatment in Wistar rats and Beagle dogs. Following both short- and long-term treatment with glepaglutide, a significant dose-dependent intestinotrophic effect was seen in both genders and species. At all doses increased length and weight of the small intestine as well as macroscopic thickening and villous hypertrophy were noted in all segments of the small intestine, without any differences between genders. The findings were still present following a 6-week recovery period, indicating long-acting intestinotrophic effects of glepaglutide. These studies demonstrate that a long-acting GLP-2 analogue (glepaglutide) has a fast onset and long duration of intestinotrophic action with similar profile in both genders and species (rat and dog).
Zobrazit více v PubMed
Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut. 2000;47(1):112–119. doi: 10.1136/gut.47.1.112. PubMed DOI PMC
Drucker DJ, Yusta B. Physiology and pharmacology of the entero-endocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561–583. doi: 10.1146/annurev-physiol-021113-170317. PubMed DOI
Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 2000;85:2884–2888. doi: 10.1210/jcem.85.8.6717. PubMed DOI
NPS Pharmaceuticals. GATTEX (teduglutide [rDNA origin]): Highlights of prescribing information. 2012.
Wallis K, Walters JR, Forbes A. Review article: glucagon-like peptide 2--current applications and future directions. Aliment Pharmacol Ther. 2007;25:365–72. doi: 10.1111/j.1365-2036.2006.03193.x. PubMed DOI
Warner BW. GLP-2 as therapy for the short-bowel syndrome. Gastroenterology. 2001;120(4):1041–1043. doi: 10.1053/gast.2001.22560. PubMed DOI
Sinclair E, Drucker DJ. Proglucagon-derived peptides: mechanisms of action and therapeutic potential. Physiology. 2005;20:357–365. doi: 10.1152/physiol.00030.2005. PubMed DOI
Tavares W, Drucker DJ, Brubaker PL. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab. 2000;278:E134–E139. doi: 10.1152/ajpendo.2000.278.1.E134. PubMed DOI
